pertuzumab;2C4;Immunoglobulin G1, anti-(human V (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer;Omnitarg;Unii-K16aiq8ctm;Pertuzumab (anti-HER2);Pertuzumab-Perjeta;Research Grade Pertuzumab(DHC09602)
MDL No.
MFCD08436787
用途
Pertuzumab is indicated for: (1) use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease; (2) use in combination with trastuzumab and docetaxel as neoadjuvant therapy for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (tumor diameter >2 cm or node-positive) as part of a complete treatment regimen for early breast cancer, based on pathological complete response rate; (3) use in combination with trastuzumab and chemotherapy as adjuvant therapy for patients with HER2-positive early breast cancer at high risk of recurrence.